NeOnc Technologies Holdings is trading 5.86% higher at $3.25, with no verified company-specific catalyst identified for the November 3 move.

  • On November 2, the company announced that NEO100 and NEO212 data will be presented at the November 13 Society for Neuro-Oncology meeting; available coverage does not establish the announcement as the cause of the rise.
  • The supplied sector context shows biotech lower, which does not explain the stock’s move higher. The advance remains unexplained by verified news.